The ability of CoronaVac to activate a cellular immunity is relevant since CD4+ and CD8+ T-cell-mediated response was significantly lower in severe/critical patients in comparison to those with mild and mid-grade groups, data that strongly support the participation of T cells in the immune protection against COVID-19 (18). This evidence concerns the gene CD8A and COVID-19.